Search

everythinglearnresearchcommunity

for

Search:↓

Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Psychosis can be an early sign of neuropsychiatric lupus, treatable with tailored medication.

Low serum complement levels in SLE patients don't always match with disease flares; monitoring C3 and C4 is useful, but cell-bound complement products might better indicate disease activity.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.

Hair loss in systemic lupus erythematosus patients is unique and improves with treatment.

Early detection and targeted management are crucial for better outcomes in systemic lupus erythematosus.

Absence of skin rash and low complement C3 levels increase the risk of lupus nephritis.

Hair chemicals don't cause SLE but may increase skin issues in those with SLE.

Belimumab may cause hair loss in lupus patients.

Fever and rash can be early signs of lupus.

Adding colchicine stopped the girl's recurring heart issues caused by lupus.

NKG2D gene polymorphism doesn't affect SLE risk but may influence symptoms like rash and hair loss.

Diagnosing new systemic lupus during pregnancy is hard but important for the health of the mother and baby.

Fibromyalgia slightly more common in SLE patients but doesn't affect SLE activity assessments.

Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

An imbalance in gut bacteria is linked to skin immune diseases and may affect their outcomes and related health issues.

New treatments for lupus show promise, but more research is needed, especially for children.

SLE patients experience two patterns of non-inflammatory symptoms: intermittent and persistent.

Women with Systemic Lupus Erythematosus should have closely monitored pregnancies and avoid certain medications to improve their pregnancy outcomes.

The mtDNA N haplogroup is linked to a higher risk of late-onset lupus and specific symptoms in Han Chinese women.

Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.

Hair loss can indicate or worsen with systemic diseases, and treating the underlying condition is important.

Environmental factors like diet and vitamin levels, especially Vitamin D, can affect autoimmune diseases differently, with lifestyle changes potentially improving outcomes.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

Early detection and infection prevention are crucial for improving survival in pediatric lupus patients with aplastic anemia.